Shares of INC Research Holdings Inc (NASDAQ:INCR) have been assigned an average recommendation of “Hold” from the ten ratings firms that are currently covering the firm. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $55.00.
INCR has been the topic of a number of research analyst reports. TheStreet downgraded INC Research Holdings from a “b-” rating to a “c” rating in a research report on Thursday, March 23rd. SunTrust Banks, Inc. downgraded INC Research Holdings from a “buy” rating to a “hold” rating and set a $48.00 target price on the stock. in a research report on Monday, March 20th. Goldman Sachs Group Inc downgraded INC Research Holdings from a “conviction-buy” rating to a “buy” rating and set a $51.00 target price on the stock. in a research report on Wednesday, March 1st. Jefferies Group LLC boosted their target price on INC Research Holdings from $56.00 to $59.00 and gave the stock a “buy” rating in a research report on Tuesday, January 24th. Finally, William Blair reiterated an “outperform” rating on shares of INC Research Holdings in a research report on Wednesday, March 1st.
Shares of INC Research Holdings (NASDAQ:INCR) opened at 55.70 on Monday. INC Research Holdings has a 12-month low of $36.70 and a 12-month high of $57.25. The stock’s 50 day moving average price is $47.06 and its 200 day moving average price is $49.22. The company has a market capitalization of $3.01 billion, a PE ratio of 26.50 and a beta of 1.74.
INC Research Holdings (NASDAQ:INCR) last announced its quarterly earnings data on Wednesday, May 10th. The company reported $0.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.05. INC Research Holdings had a return on equity of 49.42% and a net margin of 6.58%. The business had revenue of $252.10 million for the quarter, compared to the consensus estimate of $250.76 million. During the same period in the previous year, the business earned $0.58 earnings per share. The business’s revenue was up 1.2% on a year-over-year basis. On average, equities research analysts forecast that INC Research Holdings will post $2.68 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “INC Research Holdings Inc (INCR) Given Consensus Rating of “Hold” by Analysts” was first posted by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/inc-research-holdings-inc-incr-given-consensus-rating-of-hold-by-brokerages-updated/652376.html.
In other news, CEO Alistair Macdonald sold 9,467 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $45.00, for a total transaction of $426,015.00. Following the transaction, the chief executive officer now owns 83,935 shares of the company’s stock, valued at $3,777,075. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Christopher L. Gaenzle sold 4,733 shares of the company’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $45.70, for a total value of $216,298.10. Following the transaction, the chief accounting officer now directly owns 53,050 shares in the company, valued at approximately $2,424,385. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,028 shares of company stock worth $1,039,573. Company insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. boosted its position in INC Research Holdings by 39.8% in the third quarter. UBS Asset Management Americas Inc. now owns 30,081 shares of the company’s stock worth $1,341,000 after buying an additional 8,560 shares in the last quarter. Buffington Mohr McNeal acquired a new position in INC Research Holdings during the third quarter worth approximately $2,545,000. Bank of New York Mellon Corp boosted its position in INC Research Holdings by 9.2% in the third quarter. Bank of New York Mellon Corp now owns 271,550 shares of the company’s stock worth $12,105,000 after buying an additional 22,918 shares in the last quarter. DUPONT CAPITAL MANAGEMENT Corp boosted its position in INC Research Holdings by 62.1% in the third quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 59,285 shares of the company’s stock worth $2,643,000 after buying an additional 22,715 shares in the last quarter. Finally, National Investment Services Inc. WI acquired a new position in INC Research Holdings during the third quarter worth approximately $244,000. 99.79% of the stock is currently owned by hedge funds and other institutional investors.
INC Research Holdings Company Profile
INC Research Holdings, Inc is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for INC Research Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INC Research Holdings Inc and related companies with our FREE daily email newsletter.